TORONTO, March 3, 2022 /PRNewswire/ -- Field Trip Health
Ltd. (NASDAQ: FTRP, TSX: FTRP) ("Field Trip"), a global leader in
the development and delivery of psychedelic-assisted psychotherapy,
today announced a strategic partnership with Cerebral, the fastest
growing online mental health platform. The companies are launching
a partnership where Cerebral clinicians can refer qualified clients
to Field Trip Health's ketamine assisted therapy, while Field Trip
will connect potential clients seeking general psychiatry and
teletherapy services to Cerebral. This end-to-end solution will
provide personalized treatment solutions for those seeking to
improve their mental health.
Field Trip Health currently has clinics operating in eight major
U.S. cities, making it the largest provider of psychedelic-assisted
therapies in North America. With
this partnership, Field Trip Health patients will have access to
services beyond psychedelic treatments and can now access a
holistic offering of mental health treatments through Cerebral.
"Our partnership with Cerebral will lower the barriers of entry
into ketamine assisted therapy for many people who have solely been
exposed to generalized psychiatry or might have not been presented
with an alternative of exploring a healing journey propelled
through psychedelics," said Ronan
Levy, Field Trip's Executive Chairman. "We're excited to be
Cerebral's preferred platform to refer patients to. Together we
will help change the mental health landscape by bringing together
teletherapy, telepsychiatry, and psychedelic-assisted therapy and
offer more comprehensive benefits to consumers' mental
health."
Cerebral's mission is to improve access to long-term,
high-quality comprehensive mental health care through affordable
plans on their online mental health platform which provides
comprehensive care including therapy, counseling, and medication
management. Cerebral's platform allows members to schedule and meet
with their care team online and provides medication management and
delivery straight to your door.
"The recent shift in the mental health landscape has
resulted in a need for modernized, digitized, and personalized
solutions. At its core, Cerebral believes that everyone deserves
access to individualized, non-judgmental mental health care," added
Dr. David Mou, Cerebral's Chief
Medical Officer. "We're constantly searching for novel ways to work
towards that goal, which is why we chose to partner with Field
Trip, a like-minded company with an aligning ethos that brings
psychedelic-assisted psychotherapy to the table for our
clients,"
About Field Trip Health Ltd.
Field Trip is a global leader in the development and delivery of
psychedelic therapies. With our Field Trip Discovery division
leading the development of the next generation of psychedelic
molecules and conducting advanced research on plant-based
psychedelics and our Field Trip Health division building centers
for psychedelic therapies opening across North America and Europe along with the digital and
technological tools that will enable massive scale, we help people
in need with a simple, evidence-based way to heal and heighten
engagement with the world.
Learn more at: www.fieldtriphealth.com
Follow us on Twitter and Instagram: @fieldtriphealth
About Cerebral
Cerebral's mission is simple and straightforward: To improve
access to long-term, high-quality mental health care to all. Unlike
traditional mental health care, Cerebral is accessible, convenient,
affordable, and free of stigma. With several full-service monthly
subscription plans to choose from, members receive online access to
prescribing providers, behavioral counselors, and talk
therapists—all from the comfort of home or anywhere else with an
internet connection. Visits are done via video chat, and members
can message their care team directly. Members can even receive
medications delivered straight to their door (if prescribed).
Cerebral was founded and launched in January
2020 by CEO Kyle Robertson.
For more information, visit www.cerebral.com
To receive company updates about Field Trip and to be added to
the email distribution list please sign up here.
Cautionary Note Regarding Forward-Looking
Information.
This release includes forward-looking information (within the
meaning of Canadian securities laws and within the meaning of the
United States Private Securities Litigation Reform Act of 1995)
regarding Field Trip and its business. Often but not always,
forward-looking information can be identified by the use of words
such as "expect", "intends", "anticipated", "believes" or
variations (including negative variations) of such words and
phrases, or state that certain actions, events or results "may",
"could", "would" or "will" be taken, occur or be achieved. Such
statements are based on the current expectations and views of
future events of the management of Field Trip, and are based on
assumptions and subject to risks and uncertainties. Although the
management of Field Trip believes that the assumptions underlying
these statements are reasonable, they may prove to be incorrect.
The forward-looking events and circumstances discussed in this
release may not occur and could differ materially as a result of
known and unknown risk factors and uncertainties affecting the
companies, including commencement, uptake and success of the
referral relationship between Cerebral and Field Trip, factors
affecting the medical clinic industry, market conditions, economic
factors, management's ability to manage and to operate the business
and the equity markets generally. Although Field Trip has attempted
to identify important factors that could cause actual actions,
events or results to differ materially from those described in
forward-looking statements, there may be other factors that cause
actions, events or results to differ from those anticipated,
estimated or intended. Accordingly, readers should not place undue
reliance on any forward-looking statements or information. No
forward-looking statement can be guaranteed. Except as required by
applicable securities laws, forward-looking statements speak only
as of the date on which they are made and Field Trip does not
undertake any obligation to publicly update or revise any
forward-looking statement, whether as a result of new information,
future events, or otherwise. For a more detailed discussion of
risks and other factors, see Field Trip's amended Annual
Information Form dated July 16, 2021
under the heading "Risk Factors", or otherwise disclosed in the
public filings made with applicable securities regulatory
authorities and available under Field Trip's SEDAR and EDGAR
profiles.
This press release does not constitute an offer to sell or the
solicitation of an offer to buy securities.
Neither the Toronto Stock Exchange nor its Regulation Services
Provider, have approved the contents of this release or accept
responsibility for the adequacy or accuracy of this release.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/field-trip-health-and-cerebral-partner-to-provide-end-to-end-mental-health-care-301494788.html
SOURCE Field Trip Health